Logo

Shionogi Entered into a Commercialization Agreement with Susmed for Digital Therapeutic App to Treat Insomnia

Share this
Shionogi Entered into a Commercialization Agreement with Susmed for Digital Therapeutic App to Treat Insomnia

Shionogi Entered into a Commercialization Agreement with Susmed for Digital Therapeutic App to Treat Insomnia

Shots:

  • Susmed to receive ~ $40.92M including up front and development milestones, upon closure of the agreement & is eligible to receive royalties on product sales. Additionally, both companies will provide new healthcare solutions, including joint development of digital therapeutic apps
  • Under the terms of the agreement, Shionogi will acquire the exclusive marketing rights for Digital Therapeutic App in Japan
  • The app is currently under development by Susmed. In a P-III trial, the app showed a significant improvement in the Athens insomnia scale (an index of insomnia severity). Susmed plans to submit an NDA for the digital therapeutic app for insomnia, based on the results from the P-III trial

Ref: Shionogi | Image: Shionogi

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions